Nkarta Inc
NKTX
NASDAQ
Biotechnology
$2.33
USD
+0.03 (+1.30%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $164.38M
Volume 302.4K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-117.32M
TTM
-7.4%
YoY
Operating Cash Flow
$-92.76M
TTM
+5.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 6.4 | 7.1 | 5.7 | 5.9 | 14.1 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 27.2 | 27.3 | 31.0 | 30.9 | 43.1 |
Operating Income | -27.2 | -27.3 | -31.0 | -30.9 | -43.1 |
EBITDA | -24.9 | -25.0 | -28.7 | -28.5 | -40.4 |
Other Income / Expense | 0.2 | 1.7 | 0.3 | -0.3 | 0.2 |
Total Other Income / Expense | 4.2 | 5.6 | 3.6 | 2.5 | 2.8 |
Income Before Income Taxes | -23.0 | -21.7 | -27.4 | -28.4 | -40.4 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -23.0 | -21.7 | -27.4 | -27.8 | -40.4 |
Consolidated Net Income / Loss | -23.0 | -21.7 | -27.4 | -28.4 | -40.4 |
Net Income Attributable to Common Shareholders | -23.0 | -21.7 | -27.4 | -28.4 | -40.4 |
Basic EPS | -$0.31 | -$0.29 | -$0.37 | -$0.37 | -$0.54 |
Diluted EPS | -$0.31 | -$0.29 | -$0.37 | -$0.37 | -$0.54 |
Basic Shares Outstanding | 74.0M | 74.0M | 74.0M | 74.3M | 74.5M |
Diluted Shares Outstanding | 74.0M | 74.0M | 74.0M | 74.3M | 74.5M |